Barclays’s Blueprint Medicines BPMC Stock Holding History

Barclays’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-136,900	Closed	-$13M	–	4899
2024 Q1	$13M	Sell	136,900 -7,700	-5%	-$660K	﹤0.01%	1225
2023 Q4	$13.3M	Buy	+144,600	New	+$9.37M	﹤0.01%	1308
2018 Q4	–	Sell	-30,000	Closed	-$2.34M	–	6948
2018 Q3	$2.34M	Buy	+30,000	New	+$2.09M	﹤0.01%	2699

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Barclays's BPMC Position: Q3 2025 in Review

Barclays sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 1,556,918 shares — an estimated $200M sold.

Barclays first reported a position in BPMC in Q2 2015 and held it in 41 quarters. The position peaked at $200M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

Barclays reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
Barclays sold 1,556,918 Blueprint Medicines shares in Q3 2025, an estimated $200M.
Barclays first reported a position in Blueprint Medicines in Q2 2015 and held it in 41 quarters.
Barclays's Blueprint Medicines position peaked at $200M in Q2 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Barclays's 13F filing for Q3 2025, filed 12 Nov 2025.